Realising long-acting ART as first-line treatment

Affiliations

¹ Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
² Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address: jscurrier@mednet.ucla.edu.

Comment

Tara Vijayan et al. Lancet HIV. 2023 Sep.

. 2023 Sep;10(9):e558-e559.

doi: 10.1016/S2352-3018(23)00176-5. Epub 2023 Aug 8.

¹ Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
² Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address: jscurrier@mednet.ucla.edu.

No abstract available

Conflict of interest statement

JSC reports serving on a scientific advisory board for Merck in 2021. TV declares no competing interests.

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K, Sutherland-Phillips D, Berni A, Latham CL, Zhang F, D'Amico R, Pascual Bernáldez M, Van Solingen-Ristea R, Van Eygen V, Patel P, Chounta V, Spreen WR, Garges HP, Smith K, van Wyk J. Ramgopal MN, et al. Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8. Lancet HIV. 2023. PMID: 37567205 Clinical Trial.